Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines
Abstract Dexamethasone, a common medication used in the treatment regimen of glioblastoma, has broad inhibitory effects on the immune responses. Here, in an in vitro study, we examined the effects of piroxicam, a potent substitute for dexamethasone, on peripheral blood mononuclear cells (PBMCs) co-c...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-24392-2 |
| _version_ | 1828094181242830848 |
|---|---|
| author | Jahangir Abdesheikhi Farnaz Sedghy Alireza Farsinejad Merat Mahmoudi Mahdi ranjkesh Meysam Ahmadi-Zeidabadi |
| author_facet | Jahangir Abdesheikhi Farnaz Sedghy Alireza Farsinejad Merat Mahmoudi Mahdi ranjkesh Meysam Ahmadi-Zeidabadi |
| author_sort | Jahangir Abdesheikhi |
| collection | DOAJ |
| description | Abstract Dexamethasone, a common medication used in the treatment regimen of glioblastoma, has broad inhibitory effects on the immune responses. Here, in an in vitro study, we examined the effects of piroxicam, a potent substitute for dexamethasone, on peripheral blood mononuclear cells (PBMCs) co-cultured with two glioblastoma cell lines, U-87 MG and A-172 cells. MTT assay was used to determine the proliferation of PBMCs treated with piroxicam, or dexamethasone. In addition, to evaluate the effects of drugs on the cell cycle distribution, DNA content per cell was analyzed in PBMCs and A-172 cell lines using flow cytometry. Oxidative parameters, including superoxide dismutase-3 (SOD3) activity and total anti-antioxidant capacity, lactate dehydrogenase (LDH) activity, as well as IFN-γ and TGF-β levels were measured in PBMCs alone or in the presence of cell lines using ELISA. Unlike dexamethasone, piroxicam showed a protective effect on PBMCs against both glioblastoma cell lines. Furthermore, while dexamethasone reduced the proliferation of PBMCs, piroxicam had no adverse effect on the proliferation. Cell cycle analysis showed a reduction in the G2/M phase in piroxicam-treated A-172 cells. Additionally, dexamethasone limited the cell cycle progression by increasing the fraction of PBMCs in G0/G1. Interestingly, after co-culturing piroxicam-treated PBMCs with cell lines, a remarkable rise in the LDH activity was observed. Although not significant, piroxicam partially decreased TGF-β levels in both cell lines. Our findings suggested a protective effect of piroxicam, but not dexamethasone, on PBMCs against inhibitory mechanisms of two glioblastoma cell lines, U-87 and A-172 cells. |
| first_indexed | 2024-04-11T06:55:15Z |
| format | Article |
| id | doaj.art-0c5111b1387446ba95d402381d15b271 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T06:55:15Z |
| publishDate | 2022-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-0c5111b1387446ba95d402381d15b2712022-12-22T04:39:02ZengNature PortfolioScientific Reports2045-23222022-11-0112111110.1038/s41598-022-24392-2Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell linesJahangir Abdesheikhi0Farnaz Sedghy1Alireza Farsinejad2Merat Mahmoudi3Mahdi ranjkesh4Meysam Ahmadi-Zeidabadi5Department of Immunology, School of Medicine, Kerman University of Medical SciencesDepartment of Immunology, School of Medicine, Kerman University of Medical SciencesCell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of Medical SciencesDepartment of Immunology, School of Medicine, Kerman University of Medical SciencesDepartment of Immunology, School of Medicine, Kerman University of Medical SciencesInstitute of Neuropharmacology, Neuroscience Research Center, Kerman University of Medical SciencesAbstract Dexamethasone, a common medication used in the treatment regimen of glioblastoma, has broad inhibitory effects on the immune responses. Here, in an in vitro study, we examined the effects of piroxicam, a potent substitute for dexamethasone, on peripheral blood mononuclear cells (PBMCs) co-cultured with two glioblastoma cell lines, U-87 MG and A-172 cells. MTT assay was used to determine the proliferation of PBMCs treated with piroxicam, or dexamethasone. In addition, to evaluate the effects of drugs on the cell cycle distribution, DNA content per cell was analyzed in PBMCs and A-172 cell lines using flow cytometry. Oxidative parameters, including superoxide dismutase-3 (SOD3) activity and total anti-antioxidant capacity, lactate dehydrogenase (LDH) activity, as well as IFN-γ and TGF-β levels were measured in PBMCs alone or in the presence of cell lines using ELISA. Unlike dexamethasone, piroxicam showed a protective effect on PBMCs against both glioblastoma cell lines. Furthermore, while dexamethasone reduced the proliferation of PBMCs, piroxicam had no adverse effect on the proliferation. Cell cycle analysis showed a reduction in the G2/M phase in piroxicam-treated A-172 cells. Additionally, dexamethasone limited the cell cycle progression by increasing the fraction of PBMCs in G0/G1. Interestingly, after co-culturing piroxicam-treated PBMCs with cell lines, a remarkable rise in the LDH activity was observed. Although not significant, piroxicam partially decreased TGF-β levels in both cell lines. Our findings suggested a protective effect of piroxicam, but not dexamethasone, on PBMCs against inhibitory mechanisms of two glioblastoma cell lines, U-87 and A-172 cells.https://doi.org/10.1038/s41598-022-24392-2 |
| spellingShingle | Jahangir Abdesheikhi Farnaz Sedghy Alireza Farsinejad Merat Mahmoudi Mahdi ranjkesh Meysam Ahmadi-Zeidabadi Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines Scientific Reports |
| title | Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines |
| title_full | Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines |
| title_fullStr | Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines |
| title_full_unstemmed | Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines |
| title_short | Protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines |
| title_sort | protective potential of piroxicam on human peripheral blood mononuclear cells against the suppressive capacity of glioblastoma cell lines |
| url | https://doi.org/10.1038/s41598-022-24392-2 |
| work_keys_str_mv | AT jahangirabdesheikhi protectivepotentialofpiroxicamonhumanperipheralbloodmononuclearcellsagainstthesuppressivecapacityofglioblastomacelllines AT farnazsedghy protectivepotentialofpiroxicamonhumanperipheralbloodmononuclearcellsagainstthesuppressivecapacityofglioblastomacelllines AT alirezafarsinejad protectivepotentialofpiroxicamonhumanperipheralbloodmononuclearcellsagainstthesuppressivecapacityofglioblastomacelllines AT meratmahmoudi protectivepotentialofpiroxicamonhumanperipheralbloodmononuclearcellsagainstthesuppressivecapacityofglioblastomacelllines AT mahdiranjkesh protectivepotentialofpiroxicamonhumanperipheralbloodmononuclearcellsagainstthesuppressivecapacityofglioblastomacelllines AT meysamahmadizeidabadi protectivepotentialofpiroxicamonhumanperipheralbloodmononuclearcellsagainstthesuppressivecapacityofglioblastomacelllines |